Zhejiang Hisun Pharma expanded its oncology partnership with US-based Celsion to include GEN-1, Celsion’s proprietary gene mediated, IL-12 immunotherapy. The two companies have signed a long-term technology transfer, manufacturing and commercial supply agreement that gives Hisun the China rights to GEN-1. Celsion has completed a Phase Ib trial of GEN-1 as a treatment for first-line ovarian cancer with promising results. Previously, Hisun and Celsion agreed to partner on China rights for ThermoDox®, Celsion's heat-activated liposomal encapsulation of doxorubicin. No financial details of the new agreement were disclosed.
